Amgen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

01.10.18	Amgen: FDA Approves KYPROLIS Once-Weekly In Combination With Dexamethasone (RTTNews)
25.09.18	FDA Nod For VSTM, ANAB Breathes Easy, GEMP Trims Workforce By 33% (RTTNews)
25.09.18	Amgen : Japan Oks Blincyto For Treatment Of Relapsed Or Refractory B-cell ALL (RTTNews)
21.09.18	Mylan & Biocon: CHMP Issues Positive Opinion Recommending Approval Of Fulphila (RTTNews)
07.09.18	AstraZeneca, Amgen Announce Breakthrough Therapy Designation For Tezepelumab (RTTNews)
30.08.18	MESO Awaits Next Catalyst, EC Nod For Blincyto, EOLS, BHC To Face FDA In Feb. (RTTNews)
29.08.18	Amgen Says EC Oks Expanded Indication For BLINCYTO (RTTNews)
27.08.18	Amgen Submits SNDA For KYPROLIS - Quick Facts (RTTNews)
30.07.18	Novartis Reports EU Approval Of Aimovig - Quick Facts (RTTNews)
26.07.18	Amgen Revises Guidance - Quick Facts (RTTNews)
26.07.18	Amgen Inc. Q2 adjusted earnings Beat Estimates (RTTNews)
27.06.18	Amgen Reports Top-Line Results From Phase 3 Study Of ABP 710 - Quick Facts (RTTNews)
23.06.18	Amgen: Repatha Significantly Reduces LDL-C, Non-HDL-C In High-risk Patients (RTTNews)
19.06.18	Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO® (blinatumomab) Label (PR Newswire)
13.06.18	Natural Grocers expands craft beer and wine offerings to Gresham (PR Newswire)
11.06.18	Amgen: FDA Okays Adding Positive OS Data From Phase 3 Aspire Trial To Kyprolis (RTTNews)
11.06.18	FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS® (carfilzomib) Label (PR Newswire)
09.06.18	/C O R R E C T I O N -- Amgen/ (PR Newswire)
08.06.18	Amgen: EC Approves Prolia For Patients With Glucocorticoid-Induced Osteoporosis (RTTNews)
08.06.18	European Commission Approves Prolia® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis (PR Newswire)
07.06.18	Amgen To Present At The Goldman Sachs 39th Annual Global Healthcare Conference (PR Newswire)
06.06.18	Amgen, Oklahoma Health Care Authority And University of Oklahoma's Pharmacy Management Consultants Partner To Improve Medicaid Outcomes (PR Newswire)
05.06.18	FDA Approves First Neulasta Biosimilar, HQY Hits New High, TGTX Turns Heads (RTTNews)
01.06.18	Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients... (PR Newswire)
01.06.18	Novartis Gets Positive CHMP Opinion For Aimovig For Prevention Of Migraine (RTTNews)
01.06.18	Intelligent Investor - June 1 (RTTNews)
31.05.18	Amgen And MD Anderson Announce Collaboration To Accelerate Early Stage Treatments For Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Small-Cell Lung And Other Small-Cell Cancers (PR Newswire)
23.05.18	Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment (PR Newswire)
22.05.18	Amgen Announces Voting Results Of Annual Meeting Of Stockholders (PR Newswire)
22.05.18	It's Raining FDA Approvals, NBRV, SESN Hit Trial Goals But Fail To Make A Mark (RTTNews)
22.05.18	Amgen Says FDA Approves Prolia For Glucocorticoid-Induced Osteoporosis (RTTNews)
21.05.18	FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis (PR Newswire)
18.05.18	FDA Approves Amgen's Aimovig For Preventive Treatment Of Migraine In Adults (RTTNews)
18.05.18	FDA Approves Aimovig™ (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention (PR Newswire)
16.05.18	Amgen Receives European Commission Approval For Repatha (RTTNews)
16.05.18	Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease (PR Newswire)
16.05.18	LLY Gets Headache Relief, XENE Abuzz, 3rd Time's A Charm For PFE's Epogen Biosim (RTTNews)
12.05.18	An Ear To The Pharma: 8 Stocks To Watch (VYGR, BOLD, RXII, CYAD…) (RTTNews)
10.05.18	Amgen To Present At The Bank of America Merrill Lynch 2018 Health Care Conference (PR Newswire)
02.05.18	Noble Corporation plc Reports First Quarter 2018 Results (PR Newswire)
30.04.18	Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS® (carfilzomib) Label (PR Newswire)
28.04.18	Biotech Stocks Facing FDA Decision In May (RTTNews)
27.04.18	Amgen Reports Positive CHMP Opinion For Expanded Use Of Prolia - Quick Facts (RTTNews)
27.04.18	Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia® (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis (PR Newswire)
24.04.18	Amgen Revises 2018 Guidance - Quick Facts (RTTNews)
24.04.18	Amgen Inc. Q1 adjusted earnings Beat Estimates (RTTNews)
24.04.18	Amgen Reports First Quarter 2018 Financial Results (PR Newswire)
19.04.18	Amgen Announces Webcast Of 2018 First Quarter Financial Results (PR Newswire)
19.04.18	Gaming Laboratories International (GLI®) First Lab Accredited to Test and Certify Skill-Based Amusement Machines (SBAM) in Ohio (PR Newswire)
18.04.18	Renovate America Passes Key Job-Creation Milestone (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Handel in Frankfurt: TecDAX letztendlich in Grün
22.11.24		Gewinne in Frankfurt: SDAX zum Handelsende freundlich
22.11.24		EVOTEC-Aktie verliert zweistellig: US-Unternehmen Halozyme zieht Angebot für EVOTEC zurück
22.11.24		Optimismus in Frankfurt: SDAX steigt am Nachmittag
22.11.24		Optimismus in Europa: So entwickelt sich der Euro STOXX 50 am Freitagnachmittag
22.11.24		Börse Frankfurt in Grün: TecDAX am Freitagnachmittag mit grünem Vorzeichen

22.11.24

Handel in Frankfurt: TecDAX letztendlich in Grün

22.11.24

Gewinne in Frankfurt: SDAX zum Handelsende freundlich

22.11.24

EVOTEC-Aktie verliert zweistellig: US-Unternehmen Halozyme zieht Angebot für EVOTEC zurück

22.11.24

Optimismus in Frankfurt: SDAX steigt am Nachmittag

22.11.24

Optimismus in Europa: So entwickelt sich der Euro STOXX 50 am Freitagnachmittag

22.11.24

Börse Frankfurt in Grün: TecDAX am Freitagnachmittag mit grünem Vorzeichen